Study Phase 3

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents

Trial Information

Generic NameGuselkumabProduct NameTREMFYA®Therapeutic AreaImmune System DiseasesEnrollment383% Female48.8%% White91.6%
Product ClassmAB anti-IL12 and anti-IL23Sponsor Protocol NumberCNTO1959PSA3001Data PartnerJohnson & JohnsonCondition StudiedArthritis, PsoriaticMean/Median Age (Years)48.4

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.